Navigation Links
ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
Date:11/10/2011

MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ -- ChemoCentryx, Inc. today announced positive preclinical results for its novel CCR2 antagonist at the 44th Annual Meeting of the American Society of Nephrology. CCR2 inhibition in diabetic mice resulted in rapid and robust improvements of albuminuria, serum markers of renal function, and hyperglycemia.  These data were highlighted today in a poster presentation titled "CCR2 Inhibition in Diabetic Mice Results in a Rapid and Robust Improvement of Renal Function" in Philadelphia, PA. CCX140, the Company's most advanced CCR2 antagonist is currently in Phase II clinical trials for diabetic nephropathy.  

"These results further support the clinical evaluation of CCR2 antagonists such as our lead independent drug candidate, CCX140, in renal disease," stated Thomas J. Schall, President and CEO, ChemoCentryx. "Diabetic nephropathy is the leading cause of end-stage renal disease, for which there are no current treatment options that halt or reverse disease progression. We believe CCR2 antagonism represents a potential new treatment option which would delay or prevent the onset of end-stage renal disease and therefore offer significant pharmaco-economic benefits."

Results and Study Design

Results show that treatment with a CCR2 inhibitor significantly reduced urinary albumin excretion (UAER) and albumin:creatinine ratio (ACR). Statistically significant improvements in UAER and urinary ACR were noted as early as 48 hours after initiation of treatment. Serum markers of renal function (serum creatinine and blood urea nitrogen) were also improved after 14 days of treatment. The benefits seen on renal function were observed at lower doses than those required for anti-glycemic benefit.

Male db/db mice (age 12-19 weeks) were dosed daily with the CCR2 antagonist or matching vehicle. Weekly assessments included body weight, fasting plasma glucose, serum clinical chemistry, and 2
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
2. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
3. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
4. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
5. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
6. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
7. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
8. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
9. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
10. GeoVax Presents Data at AIDS Vaccine 2008 Conference
11. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:10/1/2014)... , October 1, 2014 ... to software invited to engage around the theme, ,Commercial ...     Elsevier , ... products and services, will host a gathering of some ... issues and trends impacting healthcare today and in the ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... ... liquid medications, pharmacists are prepared to help children successfully take antiviral medications to fight the ... children are more likely to take their medicine as prescribed. , ... Columbia, MD, (PRWEB) September 17, 2009 -- As new ...
... Enrolls First Patients in Multinational Randomized, Double-Blind Brain, ... 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... company that identifies and advances a diverse portfolio of ... reported that nimotuzumab has been approved for marketing in ...
... , , , ... ITMN ) today announced that it will be collaborating with National ... of inherited genetic factors that may play a role in idiopathic ... with access to DNA collected from patients who participated in the ...
Cached Biology Technology:FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 3FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 4YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 4InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3
(Date:9/30/2014)... German . ... foods in the world. Because they grow underground, people use ... smell of truffles is not only of interest to gourmets. ... of the Goethe University Frankfurt have discovered that the smell ... are trapped inside truffle fruiting bodies. , White truffles from ...
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... fragments in Brazil that were isolated by deforestation disappeared ... published today in the journal PLoS ONE . ... extinct. The research was funded by the National ... Dinmica Biolgica de Fragmentos Florestais, Instituto Nacional de Pesquisas ...
... 2008-09 has been followed by a decline in fertility rates ... the first concerted rise in fertility rates in the developed ... "In a new study, scientists from the Vienna ... and the International Institute for Applied Systems Analysis (IIASA) identify ...
... Spanish . Top sirloin steaks have been ... safety studies. USDA microbiologist John B. Luchansky and his colleagues ... foodborne pathogen Escherichia coli O157:H7 nor any of ... popular entre. The scientists are learning more about ...
Cached Biology News:Tropical birds return to harvested rainforest areas in Brazil 2Tropical birds return to harvested rainforest areas in Brazil 3Fertility rates affected by global economic crisis 2Does grilling kill E. coli O157:H7? 2
Request Info...
Form: Concentrated Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
... Strips have hydrophobic plastic supports that retain ... with toxic/hazardous solutions. Paper segments on each ... into solution. Complementary indicator charts provide clear ... in 1pH units; In packs of 100; ...
Biology Products: